Key result
Bibliometric analysis revealed that studies on engineered exosomes for cardiovascular disease treatment robustly increased in 2020 and continued to grow through 2022.
Why the study?
Despite growing attention to engineered exosomes for CVD treatment, a bibliometric analysis regarding their application in this field had not yet been conducted.
This bibliometric analysis highlights the rapidly growing research interest and publication trends regarding engineered exosomes for cardiovascular disease treatment since 2020.
Surveys exosome research trends in CVD; leaves open questions on clinical translation pending prospective trials.
Cardiovascular disease (CVD) is the leading cause of death around the world, warranting an increasing number of studies for its treatment. Among all of its therapeutical strategies, engineered exosomes are attracting growing attention due to their excellent biocompatibility, non-immunogenicity, and favorable plasticity. Despite its increasing popularity, there is yet to be a bibliometric analysis regarding the application of exosomes in CVD treatment. Therefore, the present study assessed the current trends in engineered exosomes in treating CVD by conducting a bibliometric analysis. All associated literatures published between years 2002-2022 were collected, through the Web of Science Core Collection. Our results showed that related studies robustly increased in 2020, followed by a gradual increase from 2020 to 2022, indicating that this field attracted growing attention. Additionally, we described critical network of countries, institutions, authors, top-cited references, and keywords. The present bibliometric study provides systematic observations on engineering exosomes in treating CVD, reveals potential challenges and future direction for additional studies, and may inspire more researchers to commit to investigating treatments for CVD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied Cardiovascular disease. Engineered exosomes was evaluated on Publication trends and critical networks. Bibliometric analysis revealed that studies on engineered exosomes for cardiovascular disease treatment robustly increased in 2020 and continued to grow through 2022.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: